Transforming Digital Pathology & AI: The Path Forward - Edinburgh
Our 2026 Agenda is regularly updated. Please check back often for the latest version.
Confirmed Speakers and Panelists:
Department of Pathology of Radboud University Medical Centre in Nijmegen, The Netherlands
Jeroen Van Der Laak
AstraZeneca Computational Pathology
The Faculty of Medicine, University of Bern
Cambridge University Hospitals
NHS Foundation Trust
Taunton and Somerset NHS Trust
UKAS
The Pathologist
Helen Bristow
Edinburgh Napier University
University of Glasgow
Natasha Reid
Yale Digital Ethics Centre
Previous Speakers:
The Royal Society Turing Fellow,
The Alan Turing Institute Director, Tissue Image Analytics (TIA),
Centre Department of Computer Science University of Warwick, UK
Co-Founder PathPresenter
Associate Clinical Chief Information Officer, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust UK
Clinical & Scientific Lead Tissue Hybridisation & Digital Pathology
Precision Medicine Centre of Excellence,
Queens University Belfast
Emory University
Sheffield Teaching Hospitals
NHS Foundation Trust
Biomedical Informatics,
Vice-Chair of Anatomic Pathology,
Director of Pathology Informatics,
Director, Digital Pathology Shared Resources,
Wexner Medical Center - Department of Pathology, The Ohio State University
Past President, Institute of Biomedical Science. Clinical Pathology Service Manager, Northumbria Healthcare NHS Foundation Trust.
North East & North Cumbria Pathology Network Operational Lead.
NHS Greater Glasgow and Clyde,
Honorary Clinical Associate Professor,
University of Glasgow, Scotland, UK
All Wales Standardisation Lead,
Chair Histopath Standing Specialist Advisory Group, Betsi Cadwaladr University Health Board
Royal Infirmary of Edinburgh,
Honorary Senior Clinical Lecturer,
University of Edinburgh
Salford Royal NHS Foundation Trust
Harvard & MGB - AI for Health.
Harvard Medical School.
University of Galway, Consultant Histopathologist, University Hospital Galway
eHealth/Diagnostics Directorate,
Glasgow Royal InfirmaryDigital Services Lead for Diagnostics,
eHealth/Diagnostics Directorate,
Glasgow Royal Infirmary
Event Overview
We are delighted to host the 7th edition of our Transforming Digital Pathology and AI conference, an event that brings together researchers, clinicians and industry specialists to examine the current and emerging role of digital pathology and artificial intelligence in diagnostic practice.
Recent developments in whole slide imaging, computational pathology and AI-based analysis are reshaping diagnostic practice and research. This programme brings together methodological, translational and clinical perspectives to examine how these approaches are being developed, validated and introduced into routine pathology workflows.
The conference will focus on the practical realities of implementation, including digital infrastructure, regulatory requirements, model validation and workforce readiness. Sessions will address how healthcare systems are managing adoption at scale, and what is needed to move from pilot studies to reliable clinical use.
Ethical, legal and governance issues form a core part of the programme, with dedicated discussion on transparency, accountability and responsibility in AI-supported diagnosis.
Taking place on 14 May 2026 at Scottish Gas Murrayfield Stadium, Edinburgh, the conference offers an opportunity to engage with current research, share implementation experience, and contribute to shaping the future role of digital pathology and artificial intelligence in clinical practice. Together, we can push the boundaries of healthcare diagnostics!
Presentation titles include:
- Paragliding with AI: revealing clinically relevant tumor archetypes in digital histopathology
- Computational pathology to guide use of ADCs
- Translational digital pathology in Synergia Breast Cancer Project
- NHS home-grown IT and AI pathology solutions
- Who’s afraid of computational pathology? And who needs it?
- From Innovation to Implementation: Ethical Challenges in Digital Pathology & AI
What to expect
- Case studies and presentations from the experts on applications of AI in digital pathology
- 8 CPD Points
- Live interaction with senior speakers
- Panel discussions
- Exhibition
- Agenda geared towards networking and close collaboration
- 1-2-1 Partnering Meetings
- Keynote across a sit down breakfast
- Hands-on product/software demos from the industry’s leading tech providers
- Evening drinks reception and canapés
We look forward to welcoming you back to Edinburgh!
Check out our hugely successful past events below.
3 for 2 offer available*
* Automatically applied at checkout, cannot be used in conjunction with any other discount.
Academic / NHS / Not for Profit - £49
- Access to all agenda sessions
- CPD Accredited
- Networking Breakfast, complimentary lunch and refreshments
- Drinks reception and canapés
- 1-2-1 meetings with selected solution providers and peers
- In-Person event exclusive content such as panel discussions and roundtables
- Take home workbooks
- Discounted hotel rates
- Group rates (Please get in touch if booking for 5+ attendees)
Industry / Pharmaceutical - £199
- Access to all agenda sessions
- CPD Accredited
- Networking Breakfast, complimentary lunch and refreshments
- Drinks reception and canapés
- 1-2-1 meetings with selected solution providers and peers
- In-Person event exclusive content such as panel discussions and roundtables
- Take home workbooks
- Discounted hotel rates
- Group rates (Please get in touch if booking for 5+ attendees)
Service / Solution Provider - £499
- Access to all agenda sessions
- CPD Accredited
- Networking Breakfast, complimentary lunch and refreshments
- Drinks reception and canapés
- 1-2-1 meetings with selected solution providers and peers
- In-Person event exclusive content such as panel discussions and roundtables
- Take home workbooks
- Discounted hotel rates
- Group rates (Please get in touch if booking for 5+ attendees)
2025 Technology Partners & Exhibitors:
PharosAI will create a unique cancer ecosystem to navigate the path to AI-assisted cancer care including opportunities for drug discovery and clinical applications, democratising access to data, AI assets, technologies, and capabilities.
PharosAI unites large-scale multimodal cancer datasets with AI models through a highly-secure, trusted, federated platform, offering state-of-the-art AI tooling for use by pharma/biotech/ life-sciences, AI-pharma, and AI developers of clinical applications, in enterprises, growth companies, and research organisations.
PharosAI will also provide a “lend me an expert” concierge service, training and education in AI for clinicians, and an end-to-end product development and deployment service, helping cancer pathology services to be more easily deployed within the NHS. This will be facilitated by a best-in-class patient involvement and governance model, and fair value sharing for data providers.
PharosAI will revolutionise AI-powered cancer care, driving breakthrough therapies, clinical applications, addressing cancer’s social determinants, lowering barriers to UK SMEs, catalysing innovation and positioning the UK as a global leader in this dynamic ecosystem.
Roche has over 125 years of history fighting disease and pioneering healthcare innovations. Our digital pathology solution combines the latest hardware, software, and AI algorithms to change what’s possible in pathology.
Designed by pathologists for pathologists, our lab-ready solution combines advanced diagnostic hardware and software to provide clinical insights with digital precision. It is an integrated solution that combines innovative slide scanners, software and image analysis algorithms, working in harmony with the complete Roche diagnostic portfolio.
Digital pathology is an effective way of delivering diagnostic testing for the healthcare system today and in the future. Roche digital pathology solutions are transforming the potential of laboratories, unlocking benefits for patients, pathologists, lab managers, and NHS trusts.
Panakeia is a pioneer in AI-driven molecular profiling. The Company’s AI-driven software provides comprehensive multi-omic information (DNA, RNA, protein, metabolite changes) directly from routinely used images of tissues and cells in minutes instead of days or weeks.
The software enables same-day treatment decision-making in the clinic and fast-tracks drug development for biopharma without the need for time and resource intensive laboratory tests. Panakeia’s PANProfiler platform is available as a research use tool for patient screening in clinical trials.
The Company’s two clinical products for breast and colon cancers are built using the PANProfiler platform. These products are registered and clinically deployed in the UK with several more products in the pipeline. Headquartered in Cambridge, UK, Panakeia is focused on improving the speed and accuracy of pathology examinations for all patients.
At Evident, we are guided by the scientific spirit—innovation and
exploration are at the heart of what we do.
Committed to making people’s
lives healthier, safer, and more fulfilling, we support our customers with
solutions that solve their challenges and advance their work; whether
it’s researching medical breakthroughs, clinical diagnostics, inspecting
infrastructure, or exposing hidden toxins in consumer products. Evident Life
Science empowers scientists and researchers through collaboration and
cutting-edge life science solutions.
Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of digital scanners and microscopes for pathology, haematology, IVF, and other clinical applications as well as for research and education. For more information, visit EvidentScientific.com.
At the heart of successful pathology labs.
Epredia, powered by passionate people, offers solutions that give you increased control over your total anatomical pathology workflow. Providing end-to-end solutions, Epredia offers a diverse range of instruments and consumables that continue to transform the histology and digital pathology market and improve patient outcomes.
With over 85 years supporting anatomical pathology and world class service, customers put their trust in Epredia over a billion times every year. Every second of every hour of every day, 44 of our products are employed in the battle against cancer.
GE HealthCare is a leading global medical technology, pharmaceutical
diagnostics, and digital solutions innovator, dedicated to providing
integrated solutions, services and data analytics to make clinicians more
effective, therapies more precise, and patients healthier and happier.
Serving patients and providers for more than 125 years, GE HealthCare
is advancing connected and compassionate care, while simplifying the
patient’s journey across the care pathway. Together, we’re creating a
world where healthcare has no limits. Learn more at gehealthcare.co.uk.
Spotlight Pathology Ltd develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers. Spotlight Pathology’s products are developed in collaboration with haematopathologists and clinicians both in UK and overseas to help pathology laboratories increase diagnostic capacity, improve objectivity and minimise turn- around times for patients.
The tools integrate seamlessly with existing digital pathology infrastructure. Our Spotlight Lymphoma product can screen lymph node biopsies to identify and sub-categorise suspected lymphomas with equivalent accuracy to a specialist haematopathologist.
Integration into the clinical pathway as a triage tool has the potential to save pathologist and laboratory staff time and streamline referrals. Come to our booth to learn more about how Spotlight’s products can make a difference in your daily work. www.spotlightpathology.com
AIRA Matrix provides Artificial Intelligence solutions for Life Sciences applications. Our products and services improve efficiency, diagnostic accuracy, and turnaround times in pathology laboratory workflows.
Our diagnostic, prognostic, and predictive solutions for cancer care aid disease stratification and enable management protocols tailored to improve treatment outcomes.
Our clients and partners include leading hospitals, pharmaceutical companies, CROs, and research labs around the world.
Since 2016, Ibex has led the way in AI-powered diagnostics for pathology. We set out to transform pathology by ensuring that every patient can receive an accurate, timely and personalized cancer diagnosis.
Today, we are the most widely-deployed artificial intelligence platform in pathology. Developed by pathologists for pathologists, our solutions serve the world’s leading physicians, healthcare organizations and diagnostic providers.
Every day, we have the privilege of touching the lives of patients worldwide. We raise physician confidence, streamline diagnostic workflows, help clinicians provide more personalized diagnosis and, most importantly, enable better clinical outcomes.
Led by a team of experts in the fields of life sciences, oncology, pathology, technology, machine learning, and healthcare, Paige strives to transform cancer diagnostics.
We make it possible not only to provide additional information from digital slides to help pathologists perform their diagnostic work efficiently and confidently, but also to go beyond by extracting novel insights from digital slides that can’t be seen by the naked eye.
These unique tissue signatures have the potential to help guide treatment decisions and enable the development of novel biomarkers from tissues for diagnostic, pharmaceutical and life sciences companies.
Source LDPath, a part of Source BioScience, helps pathology labs go digital with its ground-breaking modular digital pathology and AI pathway which helps transform diagnostic processes by drastically decreasing turnaround times from sample receipt to result, to help patients access appropriate treatment as quickly as possible.
We are your guiding hand in digital pathology and AI integration.
Sierra® technology from PathQA provides colour accuracy metrics and reporting for digital pathology quality assurance and standardizes colour for scanner-agnostic AI validation using high-fidelity ICC profiles.
The Sierra Slide with VS-Profiler software measures, calibrates and regulates digital pathology scanners and images to the real ground-truth colour of histopathology.
Standardization of digital colour to the validity of real glass slides delivers true QA.
PathQA – Quality as Standard.
Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis.
With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence.
Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Leica Biosystems is headquartered in Germany and operates in over 100 countries.
Medica’s most recent service launch, MedPath, pioneers pathology solutions focused on enhancing patient care and streamlining healthcare workflows. Offering comprehensive glass slide activity, digital reporting and digital pathology services
tailored to hospitals requiring urgent support.
With a state-of-the-art digital laboratory in Runcorn, Cheshire, here’s how we can help with unparalleled efficiency and precision:
- Robust capacity: With a weekly capacity of 9000 slides, we ensure seamless transportation of specimens to our facility via our dedicated courier service or your preferred transport solution.
- Digital pathologists: Our national network of GMC registered pathologists means we can digitise slides swiftly to deliver accurate reports electronically to your site.
- Proven track record: Building on Medica’s 20 year history as the largest provider of teleradiology reporting capacity in the UK, we bring extensive experience in partnership working and solutions management.
Committed to clinical quality and efficiency, Medica can deliver innovative pathology solutions to meet the evolving needs of modern healthcare.
Visit www.medica.co.uk/pathology for further information.
Lumea leads in merging technology with pathology, developing a standardised ecosystem to transform cancer diagnostics and improve patient care. We provide an extensive suite of solutions to optimise the entire pathology workflow, emphasizing
significant ROI.
Our advanced Image Management System, central to our offerings, enhances efficiency in case and image handling with customisable AI tools, ensuring cost-effective data storage.
Lumea’s tissue-handling technology boosts tissue quality and lab efficiency. This is complemented by our comprehensive digital pathology solution, making high-quality digital pathology services affordable from biopsy to prognosis.
